Komori
JCR Pharmaceuticals (4552) · InitiativeAdvanced

Consideration of the Construction of a New Plant in Luxembourg

First written in FY2018. 3 of 4 entries say "Advanced", first in FY2019. Latest entry: FY2026.

4entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2019 – FY20262018: 120182019: 120192020: 020202021: 020212022: 020222023: 120232024: 020242025: 020252026: 12026
Same theme, other companies
Construction of a new pharmaceutical manufacturing plant in LuxembourgA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Kobe Science Park Formulation Plant (provisional name) 25,000 14,900 Subsidies and internal funds February 2025 September 2026 Expansion of pharmaceutical manufacturing capacity」

    Following the start of construction of the new formulation plant in February 2025, the project had progressed to ¥14.9 billion in payments made, planned total investment of ¥25 billion, and scheduled completion in September 2026.
  2. FY2023AdvancedAnnual report

    「August 2022 Established JCR Luxembourg S.A. in Luxembourg as the European base for global distribution management (currently a consolidated subsidiary) Kobe Science Park Formulation Plant (provisional name) 20,000 December 2024 May 2026」

    The company established a global distribution management base in Luxembourg, giving concrete form to its European operating platform. It also disclosed a new formulation plant project scheduled for completion in May 2026.
  3. FY2019AdvancedAnnual report

    「In addition, in anticipation of further technological innovation and global expansion, the company needs to make strategic capital investments. In April of this year, it began construction of the Second Investigational Drug Manufacturing Center and is also preparing to construct a new plant in the Grand Duchy of Luxembourg.」

    The new Luxembourg plant progressed from the consideration stage to the construction preparation stage. The company also disclosed the start of construction of the Second Investigational Drug Manufacturing Center.
  4. FY2018First statedAnnual report

    「In addition, to accommodate progress in global development and an increase in marketed products, the company is advancing consideration of constructing a new plant in the Grand Duchy of Luxembourg as part of its medium- to long-term capital investment strategy.」

    The company first explicitly disclosed consideration of a new plant in the Grand Duchy of Luxembourg as medium- to long-term capital investment to support global development and an increase in marketed products.
Moved together

"Commercialization, Joint Research and Licensing of J-Brain Cargo®" moved the same way as this thread, in the same document, in 3 of its 4 moves.

333332★123456
  1. ★This thread
  2. 1Commercialization, Joint Research and Licensing of J-Brain Cargo®3×
  3. 2Approval and Application Milestones for the Development Pipeline3×
  4. 3Expanding revenue from core products and strengthening the product portfolio3×
  5. 4Expansion of Proprietary Biopharmaceutical Platform Technology3×
  6. 5Development of a Manufacturing and Cell Processing Center for Investigational Drugs3×
  7. 6Development into a research-driven company with a strong global presence2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
JCR Pharmaceuticals's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Consideration of the Construction of a New Plant in Luxembourg | JCR Pharmaceuticals Co.,Ltd. (4552) | Komori